Advertisement

Therapie I pp 1-107 | Cite as

Medikamentöse Therapie

  • Deutsche Gesellschaft für Rheumatologie
  • Kommission für Qualitätssicherung
Part of the Qualitätssicherung in der Rheumatologie book series (QUALRHEUM, volume 2)

Zusammenfassung

Nichtsteroidale Antirheumatika (NSA) sind teilweise chemisch miteinander verwandte Substanzen meist mit Säurecharakter mit entzündungshemmenden, schmerzstillenden und fiebersenkenden Eigenschaften. Ihr Wirkungsmechanismus ist komplex; die viel zitierte Hemmung der Prostaglandin-Synthese ist nur ein (und bei den verschiedenen NSA sehr unterschiedlich ausgeprägter!) Wirkungsmechanismus. NSA sind bei den meisten schmerzhaften rheumatischen Erkrankungen die Mittel der ersten Wahl.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Gabriel SE, Jaakkimainen L, Bombardier C (1991) Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Int Med 115: 787–796Google Scholar
  2. 2.
    Graham DY, Agrawl NM, Roth SH (1988) Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre double blind, placebo-controlled trial. Lancet II: 1277–1280Google Scholar
  3. 3.
    Bolten W, Häntzschel H, Hengels KJ, Stockbrügger R (1991) Management der NSAR-assoziierten Gastropathie. Akt Rheumatol 16: 171–174CrossRefGoogle Scholar
  4. 1.
    Kaiser H (1990) MEMO Rheumatologie. Enke, StuttgartGoogle Scholar
  5. 2.
    Kaiser H, Kley HK (1992) Cortisontherapie ( 9. Aufl.). Urban und Schwarzenberg, MünchenGoogle Scholar
  6. 1.
    Allen RC, Gross KR, Laxer RM, Malleson PN, Beauchamp RD, Petty RE (1986) Intraarticular triamcinolon hexacetonide in the management of chronic arthritis in children. Arthr Rheum 29: 997–1001CrossRefGoogle Scholar
  7. 2.
    Ansell BM (1993) Cyclosporin A in paediatric rheumatology. Clin Exp Rheumatol 11: 113–115PubMedGoogle Scholar
  8. 3.
    David J, Vouyiouka O, Ansell BM, Hall A, Woo P (1993) Amyloidosis in juvenile chronic arthritis: A morbidity and mortality study. Clin Exp Rheumatol 11: 85–90Google Scholar
  9. 4.
    Deutsche Rheuma-Liga, Elternkreise rheumakranker Kinder (1993) Mein Kind hat Rheuma-was kann ich tun? Herausgeber: Dt RheumaLiga-Bundesverband eV, Bonn.Google Scholar
  10. 5.
    Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS, for the Pediatric Rheumatology Collaborative Study Group and the Cooperative Children’s Study Group (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 326: 1043–1049Google Scholar
  11. 6.
    Halle F, Prieur AM (1991) Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 9: 297–302PubMedGoogle Scholar
  12. 7.
    Häfner R, Truckenbrodt H, Michels H, von Altenbockum C (1991) Therapie der juvenilen chronischen Arthritis. Dt Ärzteblatt 88: 2402–2407Google Scholar
  13. 8.
    Jacobs JC (1993) Juvenile Rheumatoid Arthritis. In: Jacobs JC (Hrsg.) Pediatric Rheumatology for the Practitioner. Springer-Verlag, Berlin, S 231–359CrossRefGoogle Scholar
  14. 9.
    Lehman TJA (1993) Aggressive therapy for childhood rheumatic diseases. When are immunosuppressives appropriate? Arthritis Rheum 36: 71— 74Google Scholar
  15. 10.
    Michels H (1991) Nichtsteroidale Antirheumatika bei juveniler chronischer Arthritis. Kinder-Rheumatol 1 /3: 4–12Google Scholar
  16. 11.
    Michels H, Truckenbrodt H (1987) Improved prognosis for iridocyclitis in juvenile chronic arthritis. Clin Exp Rheumatol 5 (Suppl.): 20 (Abstract)Google Scholar
  17. 12.
    Pernice W, Schuchmann L, Dippell J, Suschke H-J, Vogel P, Truckenbrodt H, Schindera F, Humburg C, Brzoska J (1989) Therapy for systemic juvenile rheumatoid arthritis with y-interferon: A pilot study of nine patients. Arthr Rheum 32: 643–646Google Scholar
  18. 13.
    Rooney M (1992) Is there a disease-modifying drug for juvenile chronic arthritis? Br J Rheumatol 31: 635–641PubMedCrossRefGoogle Scholar
  19. 14.
    Schaller JG (1993) Therapy for childhood rheumatic diseases. Have we been doing enough? Arthr Rheum 36: 65–68CrossRefGoogle Scholar
  20. 15.
    Suschke HJ (1992) Die Behandlung der juvenilen Spondylarthritis und der reaktiven Arthritis mit Sulfasalazin. Monatsschr Kinderheilk 140: 658–660Google Scholar
  21. 16.
    von Altenbockum C, Hibler M, Spamer M, Truckenbrodt H (1993) Juvenile chronische Arthritis. Entwicklung von Achsenfehlstellungen an Hand, Knie und Fuß und ihre krankengymnastische Behandlung. Hans Marseille Verlag, MünchenGoogle Scholar
  22. 1.
    Bardin T, Enel C, Cornelis F, Salski C, Jorgensen C, Ward R, Lathrop GM (1992) Antibiotic treatment of venereal disease and Reiter’s syndrome in a Greenland population. Arthritis Rheum 35: 190–194PubMedCrossRefGoogle Scholar
  23. 2.
    Braun J, Eggens U, Sieper J (1994) Grundlagen der Therapie der reaktiven Arthritis. Wien Klin Wochenschr 106: 259–264PubMedGoogle Scholar
  24. 3.
    Fryden A, Bengtsson A, Foberg U, Svenungsson B, Castor B, Kärnell A, Schvarcz R, Lindblom B, Kihlström E (1990) Early antibiotic treatment of reactive arthritis associated with enteric infection. Clinical and serological study. Br Med J 301: 1229–1302Google Scholar
  25. 4.
    Hammer M, Wollenhaupt J (1994) Reaktive Arthritiden. In: Gerok W, Hartmann F, Pfreundschuh M, Philipp T, Schuster H-P, Sybrecht GW (Hrsg) Klinik der Gegenwart. Urban und Schwarzenberg, MünchenWien-Baltimore, XIV, 3: S1–48Google Scholar
  26. 5.
    Lauhio A, Leirisalo-Repo M, Lähdevita J, Saikku P, Repo H (1991) Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 34: 6–14PubMedCrossRefGoogle Scholar
  27. 6.
    Mielants H, Veys EM (1985) HLA-B27 related arthritis and bowel inflammation. Part I. Sulfasalazine in HLA-B27-realted reactive arthritis. J Rheumatol 12: 287–293PubMedGoogle Scholar
  28. 7.
    Pott HG, Wittenborg A, Junge-Hülsing G (1988) Long-term antibiotic treatment in eactive arthritis. Lancet 1: 245–246CrossRefGoogle Scholar
  29. 8.
    Sieper J, Braun J (1993) Möglichkeiten und Grenzen der Diagnostik bei der reaktiven Arthritis. Dtsch Med Wschr 118: 712–718PubMedCrossRefGoogle Scholar
  30. 9.
    Sieper J, Braun J, Reichardt M, Eggens U (1993) The value of specific antibody detection and culture in the diagnosis of reactive arthritis. Clin Rheumatol 12: 245–252PubMedCrossRefGoogle Scholar
  31. 10.
    Wollenhaupt J, Schmitz E, Zeidler H (1990) Chlamydien-induzierte Arthritis: Diagnose-Verlauf-Therapie. Wien Med Wochenschr 12: 302–306Google Scholar
  32. 11.
    Wollenhaupt J, Zeidler H (1993) Infekt-reaktive bakterielle Arthritis. In: Bunte H, Domschke W, Reinertz T, Reinhardt D, Tölle R, Wilmanns W (Hrsg) Therapie-Handbuch. Urban und Schwarzenberg, München-WienBaltimore, N 71–79Google Scholar
  33. 1.
    Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741–5PubMedCrossRefGoogle Scholar
  34. 2.
    Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324: 150–4CrossRefGoogle Scholar
  35. 3.
    Derksen RHWM, de Groot PhG, Kater L, Nieuwenhuis HK (1993) Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 52: 689–92Google Scholar
  36. 4.
    Euler HH, Schroeder JO, Harten P, Zeuner RA, Gutschmidt HJ (1994) Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 37: 1784–94PubMedCrossRefGoogle Scholar
  37. 5.
    Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R (1994) Long term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 12: 163–168Google Scholar
  38. 6.
    Ginzler EM, Felson DT, Anthony JM, Anderson JJ (1993) Hypertension increases the risk of renal deterioration in systemic lupus erythematosus. J Rheumatot 20: 1694–1700Google Scholar
  39. 7.
    Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332: 993–997PubMedCrossRefGoogle Scholar
  40. 8.
    Kimberley W, Abeles M (1994) A 2 year, open ended trial of methotrexate in sytemic lupus erythematosus. J Rheumatot 21: 1674–1677Google Scholar
  41. 9.
    Klippel JH (1990) Systemic lupus erythematosus. Treatment-related complications superimposed on chronic disease. JAMA 263: 1812–1815PubMedCrossRefGoogle Scholar
  42. 10.
    Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM for the Lupus Nephritis Collaborative Study Group (1992) A controlled trial on plasmapheresis therapy in severe lupus nephritis. N Engl J Med 326: 1373–9CrossRefGoogle Scholar
  43. 11.
    Schneider M, Berning T, Waldendorf M, Glaser J, Gerlach U (1990) Immunoadsorbent plasma perfusion in patients with systemic lupus erythematosus. J Rheumatol 17: 900–7PubMedGoogle Scholar
  44. 12.
    Steinberg AD, Gourley MF, Klinman DM, Tsokos GC, Scott DE, Krieg A (1991) Systemic lupus erythematosus. Ann Intern Med 115: 548–559PubMedCrossRefGoogle Scholar
  45. 13.
    Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34: 945–950PubMedCrossRefGoogle Scholar
  46. 14.
    Sztejnbok M, Stewart A, Diamond H, Kaplan D (1971) Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum 14: 639–45Google Scholar
  47. 15.
    Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, Takahara J (1994) Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 37: 551— 558Google Scholar
  48. 1.
    Cohen MD, Ginsburg WW (1990) Polymyalgia rheumatica. Rheum Dis Clin North Am 16: 325–329PubMedGoogle Scholar
  49. 2.
    Hunder GG (1990) Giant cell arteritis. Rheum Dis Clin North Am 16: 399–409PubMedGoogle Scholar
  50. 3.
    Kaiser H, Kley HK (1992) Cortisontherapie ( 9. Aufl). Urban & Schwarzenberg, MünchenGoogle Scholar
  51. 4.
    Kyle V, Hazleman BL (1989) Treatment of polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 48: 658–666PubMedCrossRefGoogle Scholar
  52. 5.
    Mason JC, Walport MJ (1992) Giant cell arteritis. Brit Med J 305: 68–69PubMedCrossRefGoogle Scholar
  53. 1.
    Beale PG, Meyers KEC, Thomson PD (1992) Management of renal hypertension in children with Takayasu’s arteritis using renal autografting or allo-graft transplantation in selected circumstances and total lymphoid irradiation. J Pediatric Surg 27: 836–839CrossRefGoogle Scholar
  54. 2.
    Kerr G, Hallahan C, Leavitt R, Fauci A, Hoffman G (1993) A study of 60 patients with Takayasu’s arteritis: presentation, treatment and long-term outcome. Arthr Rheum 36 (suppl): R5Google Scholar
  55. 3.
    Ohtecki H, Itoh T, Natsuaki M, Minato N, Ueno T, Suda H, Naito K, Norita H, Sakai H (1992) Aortic valve replacement for Takayasu’s arteritis. J Thorac Cardiovasc Surg 104: 482–486Google Scholar
  56. 4.
    Sharma S, Saxena A, Talwar KK, Kaul U, Mehta SN, Rajani M (1992) Renal artery stenosis caused by nonspecific arteritis ( Takayasu disease ): Results of treatment with percutaneous transluminal angioplasty. Am J Roentgenol 158: 417–422Google Scholar
  57. 1.
    American Academy of Pediatrics (1988) Intravenous gamma-globulin use in children with Kawasaki disease. Pediatrics 82: 122–123Google Scholar
  58. 2.
    Curtis N, Zheng R, Lamb JR, Levin M (1995) Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Childh 72: 308–311PubMedCrossRefGoogle Scholar
  59. 3.
    Fukushige J (1994) Incidence and clinical features of incomplete Kawasaki disease. Acta Paediat 83: 1057–1060PubMedCrossRefGoogle Scholar
  60. 4.
    Jacobs JC (1993) Systemic Vasculitis Syndromes. In: Jacobs JC (ed) Pediatric Rheumatology for the Practitioner. Springer, Berlin, pp 556–640CrossRefGoogle Scholar
  61. 5.
    Kato H, Koike S, Yokoyama T (1979) Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 63: 175–179PubMedGoogle Scholar
  62. 6.
    Koren G, Silverman E, Sundel R, Edney P, Newburger JW, Klein J, Robieux I, Laxer R, Giesbrecht E, Burns JC (1991) Decreased protein binding of salicylates in Kawasaki disease. J Pediatr 118: 456–459PubMedCrossRefGoogle Scholar
  63. 7.
    Leung DYM (1993) Kawasaki disease. Curr Opin Rheumatol 5: 41–50PubMedCrossRefGoogle Scholar
  64. 8.
    Nakamura Y, Fujita Y, Nagai M, Yanagawa H, Imada Y, Okawa S, Kawasaki T, Kato H (1991) Cardiac sequelae of Kawasaki disease in Japan: statistical analysis. Pediatrics 88: 1144–1147PubMedGoogle Scholar
  65. 9.
    Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, Mason WH, Meissner C, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen F (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324: 1633–1639PubMedCrossRefGoogle Scholar
  66. 10.
    Rowley AH, Shulman ST (1991) Current therapy for acute Kawasaki syndrome. J Pediatr 118: 987–991PubMedCrossRefGoogle Scholar
  67. 11.
    Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW (1993) Gamma globulin re-treatment in Kawasaki disease. J Pediatr 123: 657–659PubMedCrossRefGoogle Scholar
  68. 1.
    Falk RJ, Hogan S, Carey TS, Jennette C (1990) Clinical course of antineutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 113: 656–663PubMedCrossRefGoogle Scholar
  69. 2.
    Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM (1991) Cyclophosphamide pulse therapy in Wegener’s granulomatosis. Nephrol Dial Transplant 6: 531–535PubMedCrossRefGoogle Scholar
  70. 3.
    Handrock K, Reinhold-Keller E, Heller M, Rudert H, Duncker G, Gross WL (1994) Beneficial effects of low-dose Methotrexate (MTX) in Wegener’s granulomatosis ( WG ). Arthritis Rheum 37: 353Google Scholar
  71. 4.
    Hoffman GS, Leavitt RY, Kerr GS, Fauci AS (1992) The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 35: 1322–1329PubMedGoogle Scholar
  72. 5.
    Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H (1993) Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341: 1620–1622PubMedCrossRefGoogle Scholar
  73. 6.
    Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, Savage C, Adu D (1994) Birmingham vasculitis activity score ( BVAS) in systemic necrotizing vasculitis. Q J Med 87: 671–78Google Scholar
  74. 7.
    Mathieson PW, Cobbold SP, Hale G, Clark MR, Oliveira DBG, Lockwood CM, Waldmann H (1990) Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med 323: 250–255PubMedCrossRefGoogle Scholar
  75. 8.
    Rees AJ, Pusey CD (1990) Plasma exchange in systemic vasculitis. Netherlands J Med 36: 103–106Google Scholar
  76. 9.
    Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A, Duncker G, Gross WL (1994) Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide in Wegener’s granulomatosis. Arthritis Rheum 37: 919–924PubMedCrossRefGoogle Scholar
  77. 10.
    Richter C, Schnabel A, Csernok E, Reinhold-Keller E, Gross WL (1994) Treatment of ANCA-associated systemic vasculitis with high-dose intravenous immunglobulin. Arthritis Rheum 37: 353Google Scholar
  78. 11.
    Schmitt WH, Haubitz M, Mistry N, Brunkhorst R, Erbslöh-Möller B, Gross WL (1993) Renal Transplantation in Wegener’s granulomatosis. Lancet 342: 860PubMedCrossRefGoogle Scholar
  79. 12.
    Schollmeyer P, Grotz W (1990) Cyclosporin in the treatment of Wegener’s granulomatosis (WG) and related diseases. APMIS (Copenhagen) 19 (Suppl): 54–55CrossRefGoogle Scholar
  80. 1.
    Fukui H, Kamitsuji H, Nagao T (1989) Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch-Schönlein purpura. Thromb Res 56: 667–675PubMedCrossRefGoogle Scholar
  81. 2.
    Mollica F, Li Volti S, Garozzo R, Russo G (1992) Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactic purpura. Eur J Pediatr 151: 140–144PubMedCrossRefGoogle Scholar
  82. 3.
    Niaudet P, Murcia I, Beaufils H, Broyer M, Habib R (1993) Primary IgA nephropathies in children: Prognosis and treatment. Adv Nephrol 2: 121–140Google Scholar
  83. 4.
    Saulsbury FT (1993) Corticosteroid therapy does not prevent nephritis in Henoch-Schönlein purpura. Pediatr Nephrol 7: 69–71PubMedCrossRefGoogle Scholar
  84. 5.
    Szer IS (1994) Henoch-Schönlein purpura. Current Opin Rheumatol 6:25–31Google Scholar
  85. 1.
    Geltner D (1988) Therapeutic approaches in mixed cryoglobulinemia. Springer Seminar Immunopathol 10: 103–113CrossRefGoogle Scholar
  86. 2.
    Langlands DR, Dawkins RL, Matz LR, Cobain TJ, Goatcher P, Papadimitriou JM (1980) Arthritis associated with a crystallizing cryoprecipitable IgG paraprotein. Am J Med 68: 461–70PubMedCrossRefGoogle Scholar
  87. 3.
    Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, Zilio P, Vernocchi A, Massazza M, Vendramin G, Tanzi E, Zanetti A (1994) Interferon 2a therapy in cryoglobulinemia associated with hepatitis C virus. New Engl J Med 330: 751–756PubMedCrossRefGoogle Scholar
  88. 1.
    Hiltz RE, Cupps TR (1994) Cutaneous vasculitis. Current Opin Rheumatol 6: 20–24CrossRefGoogle Scholar
  89. 2.
    Schumacher HR, Klippel JH, Koopman WJ (1993) Primer on the Rheumatic Diseases, 10. edition, pp 146–148Google Scholar
  90. 1.
    Ringe JD (1995) Osteoporose. Thieme, Stuttgart, New YorkGoogle Scholar
  91. 1.
    Menkes CJ (1979) Is there a place for chemical and radiation synovectomy in rheumatic diseases? Rheumatol Rehabil 18: 65–77PubMedCrossRefGoogle Scholar
  92. 2.
    Müller W (1980) Die Radiosynoviorthese mit Rhenium-186 und Erbium-169-eine Übersicht. Akt Rheumatol 5: 137–145CrossRefGoogle Scholar
  93. 3.
    Rau R, Schütte H (1983) Ergebnisse der Radiosynoviorthese mit Yttrium 90 bei chronischen Synovitiden-Eine prospektive Langzeituntersuchung. Teil I: Gesamtergebnis und Einfluß lokaler Faktoren. Z Rheumatol 42: 265–270Google Scholar
  94. 1.
    Bolten W, Waldorf-Bolten E, Sarfert D, Lehmann M, Miehlke W (1990) Pharmakokinetische Untersuchungen nach zwei-bzw. vierwöchiger Felbinac-Gel-Applikation am Kniegelenk. Z Rheumatol 49: 374–377PubMedGoogle Scholar
  95. 2.
    Kidd BL, Mapp PI, Blake DR, Gibson SJ, Polak JM (1990) Neurogenic influences in arthritis. Ann Rheumat Dis 49: 649–652PubMedCrossRefGoogle Scholar
  96. 3.
    Petersen U (1994) Statement für topische Antirheumatika. Dtsch Ärztebl 91: B-2608–2610Google Scholar
  97. 4.
    Radermacher J, Jentsch D, Scholl MA, Lustinetz T, Frölich C (1991) Diclofenac concentrations in synovial fluid and plasma after application in inflammaroty and degenerative joint disease. Br J Clin Pharmac 31: 537–541CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Deutsche Gesellschaft für Rheumatologie
  • Kommission für Qualitätssicherung

There are no affiliations available

Personalised recommendations